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PRESIDENTIAL ADDRESS
From the Eastern Vascular Society
Do no harm
Keith D. Calligaro, MD, Philadelphia, PaThank you, Dr Makaroun, for your kind remarks. It has
been an honor and privilege to serve as President of the
Eastern Vascular Surgery this past year. During this ad-
dress, I will be referring to the Hippocratic Oath, which is
attributed to the great Greek physician sometime during
470-370 B.C. Many of us may not have reviewed the oath
in quite some time. In part, it states “I swear in the presence
of the Almighty and before my family, my teachers, and my
peers that according to my ability and judgment I will keep
this Oath and Stipulation. To reckon all who have taught
me this art equally dear to me as my parents and in the same
spirit and dedication to impart a knowledge of the art of
medicine to others . . . and I will seek the counsel of
particularly skilled physicians where indicated for the ben-
efit of my patient.” The first two sentences of the Oath
mention some of the individuals whom I would like to
briefly thank, namely my family, teachers, peers, past train-
ees, and partners.
I want to acknowledge my partner of almost 20 years,
Matt Dougherty. Matt is one of my closest friends and a
very loyal partner. He’s a technically gifted surgeon and
patients love him. I also want to thank all of our past
vascular fellows. One of the reasons I really enjoy my job is
the opportunity to train these young men and women.
I’ve been extremely fortunate to have had four out-
standing mentors who took particular interest in my pro-
fessional career. During my general surgery residency in
Chicago, Dale Buchbinder was Chief of Vascular Surgery
and took me under his wing. His enthusiasm for vascular
surgery and its academic nature was a very strong incentive
for me to choose vascular as a specialty. I was fortunate
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doi:10.1016/j.jvs.2009.10.106enough to train under Dr Veith at Montefiore Medical
Center in New York. Dr Veith continues to be one of the
most respected vascular surgeons in the country. Dr Veith
was instrumental in my becoming the youngest member of
the original Vascular Surgery Board of the American Board
of Surgery. He is unsurpassed in his devotion and passion
for vascular surgery. After my vascular fellowship, I came to
Pennsylvania Hospital and joined Dom DeLaurentis. I was
thrilled when Dom became President of this Society a few
years after I joined him. Dr DeLaurentis appointed me
Program Director of our vascular surgery fellowship and
later Chief of Vascular Surgery. I want to thank him for
always being available to talk things over and for his sage
advice. The fourth mentor I want to thank is Enrico Ascher.
He helped train me during my fellowship, has helped me
immeasurably during my career as a young vascular sur-
geon, and is also a close friend. I consider Enrico to be one
of the brightest and most creative thinkers in vascular
surgery. He has a great sense of humor and a great sense of
loyalty. Our friendship is one that I will always treasure.
Although he was not involved in my training, Bob Hobson
was an individual who I greatly respected, and for reasons I
am not aware of, took a keen interest in my career. He was
one of the great leaders in vascular surgery, and we all miss
him.
Lastly, I want to thank my family for being here,
especially my wife and my son. Anthony is an 11-year-old
sports fanatic who was named to the All-Star team in soccer,
basketball, and baseball. He’s also a pretty bright kid. But
most importantly, he has a great heart and is kind and
considerate to his friends. I want to thank my wife Ina for so
many things. We celebrated our 25th wedding anniversary
three months ago with a big party for many of our friends
and family. I’m continuously amazed by everything she fits
into every day. Despite a full-time job as Assistant Dean at
Temple School of Pharmacy, Ina manages to take care of
us, get Anthony to school on time, and be the best wife I
could ever hope for. She’s my best friend and the most
understanding and compassionate person I know. Ina, I
love you very much.
DO NO HARM
A common practice when giving a Presidential address
is to review past addresses to avoid repetition. After first
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that the Presidential address to the Eastern Vascular Society
by Enrico Ascher, MD, in 2004 also dealt with the Hippo-
cratic Oath.1 However, the emphasis and thrust of Dr
Ascher’s address was significantly different than mine, as I
will be focusing on one particular sentence of the oath. I
believe that vascular surgeons need to continually remind
ourselves of the essence of the Hippocratic Oath: “I will
follow that method of treatment which according to my
ability and judgment, I consider for the benefit of my
patient and abstain from whatever is harmful.” Many of us
interpret these words as meaning “Do No Harm” when
considering vascular interventions for our patients. We
need to continually ask ourselves if we are indeed helping
patients with our various endovascular and open vascular
procedures, and every day we face difficult decisions. This
topic may not be a popular one, as I am asking the vascular
community whether the interventions we perform are truly
indicated.
There may be several reasons for what may be diplo-
matically called an “overly aggressive approach” by some
vascular surgeons. It may be that there is simply a disagree-
ment about the best treatment, and surgeons believe they
are honestly helping people. It may be that vascular sur-
geons want to be busy. Young surgeons feel pressure to
operate, surgeons want to work, and there’s a certain
amount of peer pressure. Lastly, although we may not want
to admit it, some surgeons take an aggressive approach for
financial reasons. There are bills to pay.
I was privileged to co-author a paper on hospital priv-
ileges for vascular surgeons.2 Although the paper did not
directly address the proper indications for different proce-
dures, it established guidelines for hospital privileges based
on recommended number of interventions for trainees and
practitioners. I would like to examine some of the com-
monly and uncommonly performed procedures that we do
and ask if are we helping patients or doing harm to them.
Many of the following studies were performed with the
intent to determine if these interventions were beneficial or
not, and we all need to fully supports these ongoing efforts.
The first procedure I would like to discuss is carotid
endarterectomy (CEA). Patients are frequently referred to
me for a second opinion after the first vascular surgeon
recommended surgery for an asymptomatic “critical carotid
artery stenosis.” Would many vascular surgeons recom-
mend carotid surgery for an 85 year old patient with a
history of two myocardial infarctions and severe chronic
obstructive pulmonary disease (COPD) with a docu-
mented asymptomatic 95% internal carotid artery stenosis?
The Asymptomatic Carotid Artery Study (ACAS) showed
that in asymptomatic patients with 60%-99% stenosis, CEA
was associated with approximately a 6% stroke risk after five
years compared with approximately 11% for patients treated
with best medical treatment (aspirin) at that time.3 Al-
though the study showed a clear benefit of surgery, the
reality is that approximately 90% of patients who did not
undergo CEA did not suffer an ipsilateral stroke after five
years of follow-up. These results suggest that approximately20 procedures need to be performed to prevent one stroke
in five years. We must pause before recommending surgical
intervention to prevent stroke in such patients, especially
with newer agents such as Clopidogrel (Plavix) that may
potentially even further decrease the risk of stroke with
medical management. It does not make sense to perform a
prophylactic CEA in a poor risk patient or one with an
expected limited long-term survival.
Although some risk factors are not under the control of
vascular surgeons, such as need for urgent or emergent
CEA or history of ipsilateral stroke, others can be used to
modify the decision-making process concerning asymp-
tomatic patients. The Vascular Study Group of Northern
New England identified preoperative risks for stroke or
death in 2,714 patients undergoing 3,092 primary CEAs at
11 hospitals.4 In this study, preoperative risk factors that
increased the risk of perioperative stroke included conges-
tive heart failure (CHF), age more than 70 years, and
contralateral carotid occlusion. Based on these results, vas-
cular surgeons should seriously consider if prophylactic
CEA is indicated in patients older than 70 with either CHF
or contralateral occlusion. Do patients with these risk fac-
tors truly benefit from prophylactic surgery in terms of
long-term benefits?
What impact does renal failure have on CEA? In a
report of 22,080 patients who underwent CEA for symp-
tomatic and asymptomatic carotid stenosis at 123 Veterans
Affairs Medical Centers as part of the National Surgical
Quality Improvement Program (NSQIP), patients with
moderate renal insufficiency (glomerular filtration rate
[GFR], 30-59 mL/min/1.73 m2) were found to have
significantly increased cardiac (1.7% vs. 0.9%, P  .001)
and pulmonary (2.1% vs. 1.3%, P  .001) complications
compared with controls.5 Patients with severe renal insuf-
ficiency (GFR  30 mL/min/1.73 m2) had significantly
higher peri-operative mortality (3.1% vs. 1.0% control, P
.001). Vascular surgeons must question whether we are
benefiting or causing harm to patients with renal insuffi-
ciency by subjecting them to CEA, even if they are symp-
tomatic, when newer agents such as Clopidogrel are avail-
able.
One of the most controversial treatment modalities in
vascular surgery today is carotid artery balloon angioplasty
and stenting (CAS) compared with CEA. Current Centers
for Medicare and Medicaid Services (CMS) policy limits
reimbursements for CAS to only high-risk symptomatic
patients. Despite these recommendations, a review by Step-
pacher et al showed that 91% of CAS procedures performed
in New York and Florida in 2005 and 2006 by interven-
tional cardiologists, interventional radiologists, and vascu-
lar surgeons were performed for asymptomatic disease.6
There is no Level I evidence supporting CAS as superior to
medical management for asymptomatic patients. It is diffi-
cult to believe that most of these interventionalists were
participating in industry-sponsored registries, which reim-
bursed for CAS in asymptomatic patients as part of a trial.
As William Mackey, MD, stated in his Invited Commentary
for this article, the fact that so many patients were treated
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“. . . locally prevailing opinion, individual whim, and finan-
cial motives.”7
Although many single-center, retrospective studies
have suggested very low complication rates, other multi-
center trials such as the French Endarterectomy vs Angio-
plasty in Patients with Symptomatic Severe Carotid Steno-
sis and the Stent-Supported Percutaneous Angioplasty of
the Carotid Artery vs Endarterectomy trial have docu-
mented high stroke rates with CAS, especially in compari-
son to CEA.8,9 However, these studies were criticized
because of the low percentage of patients treated with
embolic protection devices.
Certain risk factors may play a role in increasing the
complication rate of CAS, such as age more than 80 years,
atherosclerotic aortic arch, symptoms, and renal failure. In
one single-center study, CAS in patients with creatinine 
1.3 mg/dl was associated with 37% complication rate and
11.1% stroke rate.10 Clearly, a peri-procedural stroke rate
this high in a particular patient population will not be
beneficial, whether they are symptomatic or not.
Many interventionalists originally believed that CAS
would benefit “high-risk” elderly patients because of the
potential high morbidity of CEA in these patients. How-
ever, age has been shown to be a most significant factor in
outcome prediction of CAS with patients  80 years old
doing much worse than younger patients as seen during the
lead-in phase of the Carotid Revascularization Endarterec-
tomy vs Stenting Trial.11 In this study, the 30-day death/
stroke rate for patients  80 years old was 12.1%. In the
Carotid RX Acculink/RX Accunet Post Approval Trial to
Uncover Unanticipated or Rare Events 3500 study, the
30-day death/stroke/MI rate was 17.1% in symptomatic
elderly patients and 8% in asymptomatic elderly patients.12
Based on these results, CAS should rarely be recommended
for patients  80 years old so as not to do harm to these
patients.
In a review of 135,701 patients who underwent CEA or
CAS culled from a Nationwide Inpatient Sample in 2005,
postoperative stroke rates, mortality rates, and median total
hospital charges were significantly higher for patients who
underwent stenting compared with open surgery.13 The
most dramatic finding was in symptomatic patients who
underwent CAS, where the mortality rate was 4.6% and was
significantly higher (1.4%) compared with patients who
underwent CEA (P .05). Interventionalists should pause
and consider if approximately a 5% mortality rate associated
with CAS is truly helpful even in symptomatic patients.
Benefits of renal artery bypasses should also be ques-
tioned. The National Inpatient Sample (NIS) was analyzed
to identify patients undergoing renal artery bypass between
2000 and 2004.14 Renal artery bypasses were performed in
combination with open abdominal aortic aneurysms (AAA;
0.6% of all renal bypasses), thoracoabdominal aortic aneu-
rysm (TAAA) repair (0.3%), or aortobifemoral bypass
(29.5%). The hospital mortality rate was 10.1% for renal
bypasses performed for atherosclerosis, 11.5% with AAA
repair, 9.9% with aortobifemoral bypass, and 9.9% whenperformed alone. Increased risk was associated with increas-
ing age, female gender, chronic renal failure, congestive
heart failure, and chronic lung disease. The authors found
that patients treated at high-volume centers had lower
mortality rates. Nonetheless, how many vascular surgeons
inform their patients that there is approximately a 10%
chance of dying from a renal artery bypass?
The number of renal arteries treated by balloon angio-
plasty and stenting (RA-PTAS) has exploded in recent years
as cardiologists, radiologists, and vascular surgeons have
embraced this technology.15,16 In a series from Wake For-
est University, a center that is renowned for treating renal
artery disease, the results of renal artery balloon angioplasty
and stenting were less than overwhelming.17 In 110 RA-
PTAS performed on 99 patients, hypertension was cured in
1.1%, improved in 20.5%, and unchanged in 78.4%. Esti-
mated glomerular filtration rate (eGFR) was improved in
27.7%, unchanged in 65.1%, and worsened in 7.2%. There-
fore, although the procedure had a low complication rate,
RA-PTA improved hypertension or renal function in only
approximately one-quarter of patients and did not help or
actually harmed three-quarters of patients. The authors
concluded that the clinical relevance of early favorable
changes after RA-PTAS appeared limited when assessed in
a categorical fashion.
Recently some vascular surgeons have questioned
whether indications for repair of abdominal aortic aneu-
rysms (AAAs) should be liberalized despite the fact that two
randomized studies concluded that early elective open sur-
gery did not confer any late survival advantage in patients
with AAAs as small as 4.0-5.5 cm, unless the aneurysm grew
quickly or became symptomatic.18,19 What about the fittest
patients with expected excellent long-term survival? Based
on a probability index analysis of the UK Small Aneurysm
Trial, early elective surgery did not confer any survival
benefit even in fit patients with small AAAs.20 A prospec-
tive, randomized, multi-center trial was designed to deter-
mine if there was a benefit of intervening for small aneu-
rysms with endovascular aortic aneurysm repair (EVAR),
since the morbidity and mortality with this intervention has
been very low.21 During presentation of late-breaking clin-
ical trials at the Vascular Annual Meeting (June 11-14,
2009), the Positive Impact of Endovascular Options for
Treating Aneurysms Early investigators presented data
showing there was no difference in aneurysm-related mor-
tality, rupture, or survival between patients randomized to
early endovascular repair or ultrasound surveillance for
4.0-5.0 cm AAAs. Based on these results, vascular surgeons
should recommend surgery for AAAs  5.0 cm, regardless
of whether open or endovascular repair is being considered,
only for rapidly expanding aneurysms or rupture.
Identification of appropriate risk factors can help deter-
mine the suitability for recommending aortic surgery. In a
derivation cohort of 11,415 open and 11,415 endovascular
elective AAAs repairs in Medicare beneficiaries from 2001
to 2004, increased absolute predicted mortality was associ-
ated with increasing age, type of repair (open vs endovas-
cular), female gender, dialysis-dependency, congestive
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surgeons recommend open surgical repair for an 82-year-
old, dialysis-dependent female with a history of CHF who
presented with an asymptomatic 8 cm AAA and who was
not a candidate for EVAR? This study predicted that pa-
tients  80 years old with all risk factors were predicted to
have a peri-operative mortality of 38% for elective open
AAA surgery. The vascular surgeon must give serious con-
sideration whether recommending open surgery is truly in
the best interest of patients with some or all of these risk
factors.
Several series have documented the high-mortality and
paralysis rate associated with open repair of descending
thoracic and thoracoabdominal aneurysms in state-wide or
national surveys. In a national in-patient sample (NIS) of
1,976 open surgical repair of intact descending thoracic
aortic aneurysms between 1988 and 2003, in-hospital mor-
tality for patients 75 years or older was 17.6%.23 Even when
all age groups were considered, 30-day mortality for intact
thoraco-abdominal aneurysm repair was 19% between
1991 and 2002 in a California state-wide database.24
In an effort to expand the indications for treating
thoracoabdominal aneurysms with endografts and avoiding
a thoracotomy, hybrid operations have been proposed that
combine an open abdominal operation, namely visceral
and/or renal debranching, and endovascular grafting of the
thoracoabdominal aneurysm. However, the abdominal por-
tion of the operation is time-consuming and complicated, and
the appropriateness of performing hybrid procedure should
be questioned. In a series from Massachusetts General Hos-
pital, composite mortality and/or permanent paraplegia oc-
curred in 21.7% of 23 high-risk patients who underwent the
hybrid repair.25 Also, 10% (7/70) of visceral/renal grafts
occluded during follow-up. Even more alarming was a 40%
composite mortality and/or permanent paraplegia rate in
lower risk patients who underwent the hybrid operation.
The authors concluded that the hybrid thoracoabdominal
repair in high-risk patients had such significant morbidity
and mortality that a non-interventional approach may be
the more appropriate choice in many patients. In other
words, the authors concluded that many high-risk patients
with these aneurysms are best treated by “doing no harm”
and not intervening.
Although it is becoming increasingly accepted that
repair of descending thoracic aneurysms has better results
with endovascular treatment than open surgery, patient
selection remains a critically important factor whether any
intervention should be recommended, especially when late
outcomes are considered. In a series from Stanford of 103
patients, a five-year survival estimate of 31% was reported in
patients who were considered inoperable and who were
treated with endovascular repair compared with 78% for
those who were open surgical candidates.26 Reflecting
on this article in a review of endovascular repair of descend-
ing thoracic aneurysms, the in-coming President of the
Eastern Vascular Society, Michel S. Makaroun, MD, con-
cluded “This brings into question the appropriateness ofany treatment in asymptomatic high-risk patients.”27
Again, we need to remind ourselves “Do No Harm.”
The potential high morbidity and mortality of infrain-
guinal bypass surgery in the very elderly is cause for con-
cern. In a series of 150 lower extremity bypasses performed
in patients  90 years old for limb salvage between 1996
and 2006 from Albany Medical College, the peri-operative
mortality was 15% (vs. 3% in 5,443 bypasses in patients 
90 years old) and the one-year mortality was 45% (vs. 11%
in patients  90 years old).28 The authors concluded that
the significantly higher mortality rate should “. . . temper
the enthusiasm for an aggressive approach to limb sal-
vage . . .” in patients  90 years old. Vascular surgeons
should question whether we are doing harm to these elderly
patients with attempted open revascularization. In a series
from the State University of New York at Buffalo, the
perioperative mortality was similarly 16.2% in patients 80
years old who underwent infrainguinal open revasculariza-
tion for limb salvage compared with 2.9% (P  .009) in
patients  80 years old.29 These authors concluded that
“open procedures carry a high peri-operative morality in
the  80 year old age group and should be avoided if
possible.”
Renal failure in octogenarians has a particularly omi-
nous prognosis when open infrainguinal bypass surgery is
performed. In a series of 2,404 infrainguinal bypasses gath-
ered from the National Surgical Quality Improvement Pro-
gram (NSQIP) in 2005 and 2006, the overall mortality was
2.7% and major complication rate was 18.7%.30 The com-
bination of dialysis and age  80 years resulted in a 13.3
times higher risk of death and 2.2 times higher risk of major
complications. The authors concluded that “. . . stringent
indications should be maintained due to the significant
associated perioperative morbidity . . .,” especially in dial-
ysis patients 80 years old, when considering infrainguinal
bypass surgery.
Risk stratification may be possible in patients with
critical limb ischemia and may help to identify patients who
should not undergo bypass surgery but instead be treated
with endovascular intervention or primary amputation. In a
series of patients who underwent infrainguinal vein bypass
surgery for chronic limb ischemia, data was compiled from
the Project of Ex-Vivo Graft Engineering via Transfection
III randomized trial (n 1,404) and a multicenter registry
(n  716) from three vascular centers.31 Their analysis
identified a high-risk group of patients with chronic limb
ischemia with a50% chance of death or major amputation
at one year. The authors identified dialysis, tissue loss, age
75, hematocrit  30, and advanced coronary artery dis-
ease as five significant predictors associated with poor am-
putation-free survival. Risk stratification methods might
help vascular surgeons decide if infrainguinal bypass surgery
is indicated, especially for dialysis-dependent patients 80
years old.
So should a minimally invasive endovascular procedure
be performed as the first step in poor risk patients to treat
chronic lower extremity arterial occlusive disease? In a series
of 306 threatened limbs treated by superficial femoral ar-
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tients with poor run-off had five-year cumulative patency
rates of 52% 7% but had limb salvage rates of only 20%
6%, and freedom from recurrent symptoms of only 18% 
9%.32 The authors concluded that patients with poor run-
off may not benefit from percutaneous treatment of super-
ficial femoral artery disease and may be better served by
open surgical bypass.
Another issue to take into account in order to “Do No
Harm” is that hospital surgical volume for a particular
procedure correlates with operative mortality. Birkmeyer
showed that mortality for CEA, lower extremity bypass,
and open AAA repair was lower in high-volume hospitals in
the United States compared with low-volume hospitals.33
A similar finding occurred in a study comparing open AAA
repairs between high- and low-volume hospitals, which
showed an absolute risk reduction of 3.3% for high-volume
hospitals.34 The previously mentioned review from the
University of Texas Southwest documented a nearly 5% risk
reduction observed for renal artery bypass operations per-
formed on low-risk patients in high-volume hospitals com-
pared with low-volume hospitals.14
WHAT WE’RE DOING WELL
Although vascular surgeons need to carefully assess
whether any intervention is best for the patients we treat
every day, we are doing many things well. There is data to
support the concept that vascular surgeons act conscien-
tiously and with their patients’ best interests at heart.
Regional variation in delivery of health care has been doc-
umented and may be due to different local practice styles,
but geographic variation in CEA has actually been shown to
be associated with variance in disease prevalence and not
physician preference in a review of Medicare discharge data
in the United States in 2003.35 We also may be performing
CAS more selectively than other specialists, especially for
asymptomatic disease. This may reflect our capability to
offer either surgical or endovascular treatment for carotid
disease and therefore not have a bias toward one interven-
tion or the other. Although 91% of CAS procedures per-
formed in New York and Florida in 2005 and 2006 by
interventional cardiologists, interventional radiologists,
and vascular surgeons were performed for asymptomatic
disease, the lower proportion of CAS performed by vascular
surgeons may be due to more careful patient selection.6
Although vascular surgeons should pause and consider
whether poor risk patients will truly benefit from a partic-
ular open surgical or endovascular procedures, the results
of interventions in properly selected patients performed are
excellent and clearly beneficial. There have been numerous
reports of outstanding results of CEA from single centers,
but regional or national results are just as impressive. The
operation has been shown to be extremely beneficial in
preventing strokes in symptomatic patients with 70%
ipsilateral carotid artery stenosis in a prospective random-
ized study.36 The Vascular Study Group of Northern New
England reviewed 2,714 patients undergoing 3,092 pri-
mary CEAs at 11 hospitals.4 This study documented a30-day stroke or death rate of only 1.8%. This finding is
quite impressive considering that it was a prospective col-
lection of contemporary data accumulated from 50 sur-
geons in hospitals of widely varying sizes from both com-
munity and academic centers.
Although age  80 years has frequently been cited up
to this point as a marker of worse outcomes for some
vascular procedures, selective CEA in these patients may be
beneficial, especially considering that stroke is a common
cause of disability and death in this age group. In a single-
center review from Padua, Italy, the authors carefully se-
lected appropriate patients80 years old for CEA, as noted
by the fact that the incidence of cardiac and renal risk
factors were the same as compared with patients80 years
old who underwent CEA at the same institution.37 All
patients underwent pre- and postoperative evaluation by
neurology consultants. The peri-operative stroke and death
rate was 0%, the seven year freedom from stroke was 96.6%,
and the seven-year freedom from death was 52.4%. Al-
though vascular surgeons need to be careful to do no harm
in all age groups, the excellent results from this report and
others demonstrate that carefully selected patients 80
years old can be treated safely with CEA and enjoy long-
term freedom from stroke and death.
Although the indications for CAS remain controversial,
vascular surgeons perform these procedures with as low
morbidity and mortality rates as other interventionalists.6
Recent reports of elective open surgical and endovas-
cular repair of AAAs also have documented excellent out-
comes when performed by vascular surgeons. Thirty-day
and one-year mortality of elective open repair was 2.3% and
5.8%, respectively, and after EVAR was 0.5% and 5.7%,
respectively, as reported by the Vascular Study Group of
Northern New England from 2003 to 2007 with opera-
tions performed by 50 surgeons from 11 hospitals.38 Op-
erative mortality for 323 open AAA repairs at 30 days was
2.8% overall based on the Lifeline registry, a closely moni-
tored, audited, pooled, multicenter cohort.39
Extremely challenging problems such as descending
thoracic aortic aneurysms can now be repaired with en-
dografts (TEVAR). This method of treatment is associated
with reasonably low mortality and complication rates. In
the Medtronic Vascular Talent Thoracic Stent Graft System
for the Treatment of Thoracic Aortic Aneurysms trial using
the Medtronic Talent graft, 30-day mortality was 2.1%,
paraplegia was 1.5%, paraperesis was 7.2%, and stroke was
3.6%. The 12-month results showed a 3.1% aneurysm
related mortality with an endoleak rate of 12.2%.40
Although certain patient populations such as the el-
derly may be at high risk for lower extremity revasculariza-
tion, endovascular interventions may play an important role
in achieving limb salvage when patients are chosen using
appropriate selection criteria. In a series of patients with
critical limb ischemia with good run-off treated between
2001 and 2007 from the State University of New York at
Buffalo, patients 80 years treated with endovascular in-
terventions had significantly better overall improvement
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larization (61%; P  .043).29
SUMMARY
The following recommendations for elective vascular
interventions should be considered my own personal
guidelines and are expected to be controversial (Table I).
Patients 80 years old and patients with chronic renal
failure have been shown to be high risk or have poor
long-term outcomes for many interventions. Prophylactic
CEA should be performed only in low risk patients with
expected good long-term survival and only when associated
with low complications. Prophylactic CEA should not be
offered to patients with dialysis-dependent renal failure.
CAS should not be recommended for patients 80 years
old, in patients with chronic renal failure, and if CEA can be
performed (exceptions include lesions that are surgically
inaccessible or patients with history of neck radiation or
prior CEA). Renal artery bypass should not performed in
patients80 years old, in patients with moderate or severe
chronic renal failure, in low-volume hospitals, or concom-
itantly with aortic surgery, unless an individual institution
show excellent short- and long-term outcomes. Renal ar-
tery stenting should rarely be performed and possibly only
after prospective randomized studies document its efficacy.
Open AAA surgery should not be performed in dialysis-
dependent patients 80 years old. Open TAA surgery
Table I. “Do No Harm – when to avoid intervention”




with limited long-term survival
2. Dialysis-dependent
Carotid artery stenting 1. 80 years old
2. Chronic renal failure
3. CEA can otherwise be per-
formed (consider stenting if
history of radiation or prior
CEA; anatomically inaccessible)
Renal artery bypass 1. 80 years old
2. Chronic renal failure
3. Low-volume hospitals
4. Concomitant aortic surgery
Renal artery stenting Until prospective randomized
studies show benefit
Open AAA surgery 80 years old and
dialysis-dependent







For limb salvage with poor run-off
AAA, Abdominal aortic aneurysm; CEA, carotid endarterectomy; TAA,
thoracic aortic aneurysm; TEVAR, thoracic endovascular aneurysm repair.
Exceptions to these guidelines would be 1) patients considered to have a
much better long-term survival than those with similar risk factors and 2)
documented excellent results with the procedure in question at that institu-
tion.should rarely be performed in patients80 years old unlessa center has documented excellent results in these patients.
TEVAR alone or with hybrid de-branching operations
should not be carried out in poor-risk patients. Infraingui-
nal arterial bypasses should not performed in patients 90
years old and superficial femoral artery endovascular inter-
ventions should not performed for limb salvage in patients
with poor run-off.
Exceptions to the above guidelines exist, especially in
extremely good risk patients, in patients with expected
excellent long-term survival, or when the proposed proce-
dure is to be performed in a hospital with high volume and
with documented excellent results.
CONCLUSION
These studies demonstrate that risk factor analysis for
vascular procedures, specifically for factors such as age,
chronic renal failure, congestive heart failure, and hospital
volume, play a very significant role in helping determine
which patients will be helped by vascular interventions
versus those who will be harmed. Therefore, further inves-
tigations concerning outcome analysis and risk factor anal-
ysis should be encouraged. In closing, one of the most
difficult aspects of being a successful and compassionate
vascular surgeon is the balance between “Do No Harm” vs.
“Do Not Be Afraid” to perform challenging and complex
procedures while keeping the patient’s best interests in
mind. We must still encourage vascular fellows, young
vascular surgeons, and even the more mature and experi-
enced surgeons to learn new technology and embrace new
ideas.
It has been an honor to serve as the President of the
Eastern Vascular Society. Thank you.
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